PLA2G4A, phospholipase A2 group IVA, 5321

N. diseases: 202; N. variants: 15
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.040 Biomarker disease BEFREE Our study indicated that cPLA2α may promote cell-matrix adhesion <i>via</i> the FAK/paxillin pathway, which partly explains the malignant cPLA2α phenotype seen in HCC. 31516757 2019
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.040 Biomarker disease BEFREE Based on the mechanistic analysis, cPLA2α mediated both EGF- and TGF-β-induced EMT, which are essential for HCC metastasis. cPLA2α is a potentially target for novel therapies of HCC. 28649002 2017
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.040 AlteredExpression disease BEFREE The results of the present study demonstrated that elevation in the ratio of AA to PGE2 via suppression of the protein expression of cPLA2 and COX‑2 in the AA metabolic pathway is involved in the inhibitory effect of BBR in HCC. 26081696 2015
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.040 Biomarker disease BEFREE Cross-talk between peroxisome proliferator-activated receptor delta and cytosolic phospholipase A(2)alpha/cyclooxygenase-2/prostaglandin E(2) signaling pathways in human hepatocellular carcinoma cells. 17178883 2006